Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 15/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17848895 | 0.90 | JAK2 (0.53) | JAK2GSK3BDYRK1ABRD4LRRK2 | |
| SCHEMBL17848928 | 0.88 | JAK2 (0.59) | JAK2GSK3BDYRK1ABRD4LRRK2 | |
| SCHEMBL17848948 | 0.88 | JAK2 (0.59) | JAK2GSK3BDYRK1ABRD4LRRK2 | |
| SCHEMBL17848906 | 0.87 | LRRK2 (0.58) | JAK2GSK3BDYRK1ABRD4LRRK2 | |
| SCHEMBL17848911 | 0.86 | JAK2 (0.53) | JAK2GSK3BDYRK1ABRD4LRRK2 | |
| SCHEMBL17848892 | 0.84 | JAK2 (0.55) | JAK2GSK3BDYRK1ABRD4LRRK2 | |
| SCHEMBL17581408 | 0.73 | JAK2 (0.62) | JAK2GSK3BBRD4CYP2C9 | |
| SCHEMBL17581450 | 0.71 | JAK2 (0.73) | JAK2GSK3BDYRK1ABRD4LRRK2 | |
| SCHEMBL17860612 | 0.68 | JAK2 (0.68) | JAK2GSK3BDYRK1ABRD4LRRK2 | |
| SCHEMBL15223571 | 0.68 | GSK3B (1.00) | GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190055235-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2019-02-21 | — | — | US | claimed |
| US-20190055235-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2019-02-21 | — | — | US | disclosed |
| US-20190055235-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2019-02-21 | — | — | US | disclosed |
| WO-2016097870-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097870-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055235-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | JAK2 1812/4885GSK3B 1230/4885DYRK1A 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.